Skip to main content
IDWeek 2023 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Live Streamed
Live Streamed
On Demand
On Demand
Back

Erin K. McCreary, PharmD (she/her/hers)

Director of Infectious Diseases Improvement and Clinical Research Innovation
University of Pittsburgh Medical Center
Pittsburgh, PA, United States

Erin McCreary, PharmD, BCPS, BCIDP is a Clinical Assistant Professor within the University of Pittsburgh Department of Medicine, Division of Infectious Diseases (ID) and the Director of Infectious Diseases Improvement and Clinical Research Innovation for UPMC. She received her PharmD from the Auburn University Harrison School of Pharmacy and completed her PGY1 Pharmacy and PGY2 Infectious Diseases residencies at the University of Wisconsin Health.

Dr. McCreary co-chairs the UPMC COVID-19 Therapeutics Committee and served as a co-investigator for the REMAP-CAP trial, a global, adaptive, clinical trial evaluating multiple therapies for COVID-19. She currently directs the Office of Quality and Research Innovation, leading multiple clinical trials. Dr. McCreary has led system-wide implementation of multiple infectious diseases and antimicrobial stewardship initiatives and published numerous peer-reviewed manuscripts in these areas. She also served on the Society of Infectious Diseases Pharmacists Executive Board and is currently a host of Breakpoints—The SIDP Podcast.

Her practice and research interests include infectious diseases and antimicrobial stewardship in immunocompromised hosts, gram-negative resistance, and antimicrobial pharmacokinetic/pharmacodynamic optimization. She is also passionate about professional leadership, mentorship, and preceptorship.

You can find her on Twitter @erinmccreary

Disclosure(s): AbbVie Inc: Advisor/Consultant (Ongoing); GSK: Advisor/Consultant (Ongoing), Honoraria (Ongoing); La Jolla Pharmaceuticals: Advisor/Consultant (Terminated, May 1, 2022); LabSimply: Advisor/Consultant (Terminated, October 18, 2022); Merck and Company, Inc.: Advisor/Consultant (Ongoing); Shionogi & Co.,Ltd.: Advisor/Consultant (Ongoing), Honoraria (Ongoing)

Presentation(s):